A federal judge lifted an order blocking a biosimilar of Regeneron Pharmaceuticals Inc.’s blockbuster eye drug Eylea, approving the drugmaker’s deal ending patent litigation with a pair of rivals.

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Gilstrap said all the asserted patents are involved in the ITC investigation. Credo filed separate suits against TE Connectivity, Amphenol Corp. and Molex LLC in March, alleging the companies ...

Dalton, GA, May 28--FieldTurf announced it has filed a patent infringement lawsuit in U.S. Federal Court against Triexe Management Group, Inc. (d.b.a. Sportexe). In the suit, FieldTurf alleges ...

Jan Ozer: So which patent owners are you representing and why doesn't Via LA bring this suit directly? Gottfried Schüll: We do not disclose the patent owners who bring the suit traditionally (author’s ...

“The opinion observed that previous rulings from other tribunals…had similarly construed ‘runtime engine’ in a narrower sense, but these other constructions did not bind the CAFC or ...

Atlanta, GA, September 24-- Kilpatrick Stockton LLP today announced termination of patent litigation between its client Interface, Inc. and Milliken & Company (Milliken v. Interface) and entry of ...

Katherine A. Escanlar of Saiber has entered an appearance for FanDuel and its affiliates in a patent infringement suit brought by WinView IP Holdings, which accuses the daily fantasy sports giant ...

Elvis took that idea to a tailored high point with his full black leather suit designed (once again) by Bill Belew. Given that everyone was into denim at the time, Belew wanted to recreate that ...